The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...

Merck (MRK) stock in focus as the FDA approves its anticancer agent Welireg for two rare neuroendocrine tumors, expanding its ...

The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck's cancer drug to treat two ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

Food allergy in children with atopic dermatitis is associated with an increased risk for asthma, allergic rhinitis, and ...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are ...

There are many problems with the plan. It ignores the fact, for instance, that generic drugs, which make up 90% of ...

Shares of UnitedHealth and Merck are seeing declines Tuesday morning, dragging the Dow Jones Industrial Average into negative territory. ‘We started worse than broke.’ Now at 64 and 65, we have $600K ...

EARNINGS FORECAST: Merck's earnings before interest, taxes, depreciation, amortization and one-off items is forecast to come in at 1.51 billion euros, according to the consensus. The company reported ...

Merck is facing an awkward encore as one of the worst-performing blue chip stocks in 2025, sliding 23.3% year-to-date.